Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.16 USD | +1.98% | +0.98% | -44.58% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 415M |
---|---|---|---|---|---|
Net income 2024 * | -46M | Net income 2025 * | -72M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-8.88
x | P/E ratio 2025 * |
-5.82
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.86% |
Latest transcript on Anavex Life Sciences Corp.
1 day | +4.55% | ||
1 week | -1.17% | ||
Current month | -1.56% | ||
1 month | -5.07% | ||
3 months | -48.94% | ||
6 months | -25.70% | ||
Current year | -45.65% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Sandra Boenisch
DFI | Director of Finance/CFO | 43 | 15-09-30 |
Edward Hammond
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Tom Skarpelos
FOU | Founder | 57 | 04-01-22 |
Jiong Ma
CHM | Chairman | 60 | 21-05-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.07% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 5.15 | +1.78% | 271 627 |
24-03-27 | 5.06 | +4.55% | 932,846 |
24-03-26 | 4.84 | +6.37% | 1,343,834 |
24-03-25 | 4.55 | -2.36% | 1,354,802 |
24-03-22 | 4.66 | -8.81% | 1,299,203 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.65% | 415M | |
+2.56% | 108B | |
+10.02% | 104B | |
+7.92% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |